Effects of the PPAR-Agonist fenofibrate on acute and short-Term consequences of brain ischemia

Journal of Cerebral Blood Flow and Metabolism

Volumn 34, Issue 3, 2014, Pages 542-551

  Ouk, Thavarak ^a   Gautier, Sophie ^a   Pétrault, Maud ^a   Montaigne, David ^a   Maréchal, Xavier ^a   Masse, Isabelle ^a   Devedjian, Jean Christophe ^a   Deplanque, Dominique ^a   Bastide, Michèle ^a   Nevière, Rémi ^a   Duriez, Patrick ^a   Staels, Bart ^a   Pasquier, Florence ^b   Leys, Didier ^b   Bordet, Régis ^a  

^a UNIV LILLE   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

brain ischemia; inflammation; neuroprotection; peroxisome proliferator Activated receptor Alpha

Indexed keywords

ADAM10 ENDOPEPTIDASE; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; BROXURIDINE; F 6020; FENOFIBRATE; INTERCELLULAR ADHESION MOLECULE 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PRESENILIN 1; PRESENILIN 2; UNCLASSIFIED DRUG; NEUROPROTECTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; BRAIN CORTEX; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; CELL ACTIVATION; CELL PROLIFERATION; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; GRIP STRENGTH; HIPPOCAMPUS; LEUKOCYTE ADHERENCE; LEUKOCYTE ROLLING; LIVER WEIGHT; MALE; MEMORY DISORDER; MICROGLIA; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MOUSE; NERVOUS SYSTEM DEVELOPMENT; NEUROPROTECTION; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTECTION; RAT; ROTAROD TEST; SPATIAL MEMORY; VASCULAR PROTECTION; VIDEO MICROSCOPY; Y-MAZE TEST; ANIMAL; ANIMAL BEHAVIOR; C57BL MOUSE; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; DRUG POTENTIATION; MAZE TEST; MEMORY; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; TIME; VASODILATATION; WISTAR RAT;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN ISCHEMIA; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FENOFIBRATE; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; NEUROGENESIS; NEUROPROTECTIVE AGENTS; PPAR ALPHA; RATS; RATS, WISTAR; TIME FACTORS; VASODILATION;

EID: 84896723682     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2013.233     Document Type: Article

References (34)

1. del Zoppo GJ. Stroke and neurovascular protection. N Engl JMed 2006; 354: 553-555.
2. Garcia-Alloza M, Gregory J, Kuchibhotla KV, Fine S, Wei Y, Ayata C et al. Cerebrovascular lesions induce transient b-Amyloid deposition. Brain 2011; 134: 3697-3707.
3. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer?s disease. Nat Rev Neurosci 2005; 5: 347-360.
4. Pluta R, Uamek M, Jablonski M. Consideration of the ischemic basis and treatment of Alzheimer?s disease. Folia Neuropathol 2010; 48: 11-26.
5. Collino M, Patel NS, Thiemermann C. PPARs as new therapeutic targets for the treatment of cerebral ischaemia/reperfusion injury. Ther Adv Cardiovasc Dis 2008; 2: 179-197.
6. Heneka MT, Landreth GE. PPARs in the brain. Biochim Biophys Acta 2007; 1771: 1031-1045.
7. Nicolakakis N, Hamel E. The nuclear receptor PPARg as a therapeutic target for cerebrovascular and brain dysfunction in Alzheimer?s disease. Front Aging Neurosci 2010; 2: 1-10.
8. Ouk T, Potey C, Gautier S, Bastide M, Deplanque D, Staels B et al. PPARs: a potential target for a disease-modifying strategy in stroke. Curr Drug Targets 2013; 14: 752-767.
9. Cimini A, Ceru MP. Emerging roles of peroxisome proliferator-Activated receptors (PPARs) in the regulation of neural stem cells proliferation and differentiation. Stem Cell Rev 2008; 4: 293-303.
10. Cimini A, Benedetti E, D?Angelo B, Cristiano L, Falone S, Di Loreto S et al. Neuronal response of peroxisomal and peroxisome-related proteins to chronic and acute Abeta injury. Curr Alzheimer Res 2009; 6: 238-251.
11. Gervois P, Fruchart JC, Staels B. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-Activated receptors. Nat Clin Pract Endocrinol Metab 2007; 3: 145-156.
12. Deplanque D, Gele? P, Pe? trault O, Six I, Furman C, Bouly M et al. Peroxisome proliferator-Activated receptor-Alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 2003; 23: 6264-6271.
13. Moreno S, Farioli-Vecchioli S, Ceru MP. Immunolocalization of peroxisome proliferator- activated receptors and retinoid X receptors in the adult rat CNS. Neuroscience 2004; 123: 131-145.
14. Stroke Therapy Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999; 30: 2752-2758.
15. Bastide M, Gele? P, Pe? trault O, Pu Q, Caliez A, Robin E et al. Delayed cerebrovascular protective effect of lipopolysaccharide in parallel to brain ischemic tolerance. J Cereb Blood Flow Metab 2003; 23: 399-405.
16. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986; 17: 472-476.
17. Zhang L, Chen J, Li Y, Zhang ZG, Chopp M. Quantitative measurement of motor and somatosensory impairments after mild (30 min) and severe (2 h) transient middle cerebral artery occlusion in rats. J Neurol Sci 2000; 174: 141-146.
18. Zadrozniak A, Wojda E, Wlaz? A, ?uszczki JJ. Characterization of acute adverseeffect profiles of selected antiepileptic drugs in the grip-strength test in mice. Pharmacol Rep 2009; 61: 737-742.
19. Dellu F, Mayo W, Cherkaoui J, Le Moal M, Simon H. A two-Trial memory task with automated recording: study in young and aged rats. Brain Res 1992; 588: 132-139.
20. Trivedi RK, Kallem RR, Mullangi R, Srinivas NR. Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study. J Pharm Biomed Anal 2005; 39: 661-669.
21. Pe? trault O, Ouk T, Gautier S, Laprais M, Gele? P, Bastide M et al. Pharmacological neutropenia prevents endothelial dysfunction but not smooth muscle functions impairment induced by middle cerebral artery occlusion. Br J Pharmacol 2005; 144: 1051-1058.
22. Didion SP, Ryan MJ, Didion LA, Fegan PE, Sigmund CD, Faraci FM. Increased superoxide and vascular dysfunction in CuZn SOD-deficient mice. Circ Res 2002; 91: 938-944.
23. Ouk T, Laprais M, Bastide M, Mostafa K, Gautier S, Bordet R. Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection. Vascul Pharmacol 2009; 51: 323-330.
24. Ling L, Zeng J, Pei Z, Cheung RT, Hou Q, Xing S et al. Neurogenesis and angiogenesis within the ipsilateral thalamus with secondary damage after focal cortical infarction in hypertensive rats. J Cereb Blood Flow Metab 2009; 29: 1538-1546.
25. Fisher M. Injuries to the vascular endothelium: vascular wall and endothelial dysfunction. Rev Neurol Dis 2008; 5: S4-S11.
26. Guo Q, Wang G, Namura S. Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice. J Cereb Blood Flow Metab 2010; 30: 70-78.
27. Inoue H, Jiang XF, Katayama T, Osada S, Umesono K, Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferatoractivated receptor alpha in mice. Neurosci Lett 2003; 352: 203-206.
28. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke 2009; 40: 2244-2250.
29. Zhang RL, Chopp M, Zaloga C, Zhang ZG, Jiang N, Gautam SC et al. The temporal profiles of ICAM-1 protein and mRNA expression after transient MCA occlusion in the rat. Brain Res 1995; 682: 182-188.
30. Delerive P, De Bosscher K, Besnard S, Vanden Berghe W, Peters JM, Gonzalez FJ et al. Peroxisome proliferator-Activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-Talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274: 32048-32054.
31. McColl BW, Rothwell NJ, Allan SM. Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci 2007; 27: 4403-4412.
32. Klose D, Laprais M, Leroux V, Siepmann F, Deprez B, Bordet R et al. Fenofibrate-loaded PLGA microparticles: effects on ischemic stroke. Eur J Pharm Sci 2009; 37: 43-52.
33. Iadecola C. The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 2010; 120: 287-296.
34. Pluta R. Alzheimer lesions after ischemia-reperfusion brain injury. Folia Neuropathol 2004; 42: 181-186.